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to maintain normotension. All horses were mechanically ventilated to maintain end-tidal carbon dioxide
pressures at 45 ± 5 mmHg (5.3–6.7 kPa). Heart rate (HR), invasive arterial blood pressures, inspired and
expired gas compositions, pH, arterial blood gases, electrolytes, lactate and glucose were measured. For
recovery all horses received intramuscular morphine 0.1 mg kg1 and medetomidine 2 ฀g kg1 or xylazine
0.3 mg kg1 IV. Recovery was timed and scored using three different scoring systems. Plasma samples
to measure medetomidine and xylazine concentrations were collected at predetermined timepoints. Re-
peatedly measured parameters were analyzed using a two-way repeated-measures analysis of variance for
differences between groups and over time; p lt; 0.05 was considered statistically significant.Results: Mean
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despite significant lower dobutamine doses (p = 0.0003). Other measured parameters were within clini-
cally acceptable ranges. Plasma levels were at steady state during anesthesia (MED 2.194 ± 0.073; XYL
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= 0.027) and time to standing (MED 62.0 ± 2.86; XYL 48.8 ± 3.01 min; p = 0.002) were significantly
shorter in group XYL compared to group MED. Recovery scores did not differ significantly between
groups.Conclusion and Clinical Relevance: In horses anesthetized with isoflurane and medetomidine or
xylazine, xylazine maintained higher MAP, reduced the dobutamine consumption and recovery time,
whilst overall recovery quality was unaffected.
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Introduction: To assess drug plasma levels, preanesthetic sedation, cardiopulmonary
effects during anesthesia and recovery in horses anesthetized with isoflurane combined
with medetomidine or xylazine.
Study design: Prospective blinded randomized clinical study.
Animals: Sixty horses undergoing elective surgery.
Methods: Thirty minutes after administration of antibiotics, flunixine meglumine or
phenylbutazone and acepromazine horses received medetomidine 7 µg kg−1 (group
MED) or xylazine 1.1mg kg−1 (group XYL) slowly intravenously (IV) and sedation was
assessed 3min later. Anesthesia was induced with ketamine/diazepam and maintained
with isoflurane in oxygen/air and medetomidine 3.5 µg kg−1 h−1 or xylazine 0.69mg
kg−1 h−1. Ringer’s acetate 10mL kg−1 h−1 and dobutamine were administered to
maintain normotension. All horses were mechanically ventilated to maintain end-tidal
carbon dioxide pressures at 45 ± 5 mmHg (5.3–6.7 kPa). Heart rate (HR), invasive
arterial blood pressures, inspired and expired gas compositions, pH, arterial blood
gases, electrolytes, lactate and glucose were measured. For recovery all horses received
intramuscular morphine 0.1mg kg−1 and medetomidine 2 µg kg−1 or xylazine 0.3mg
kg−1 IV. Recovery was timed and scored using three different scoring systems. Plasma
samples to measure medetomidine and xylazine concentrations were collected at
predetermined timepoints. Repeatedly measured parameters were analyzed using a
two-way repeated-measures analysis of variance for differences between groups and
over time; p < 0.05 was considered statistically significant.
Results: Mean arterial blood pressures (MAP) stayed within normal ranges but were
higher (p= 0.011) in group XYL despite significant lower dobutamine doses (p= 0.0003).
Other measured parameters were within clinically acceptable ranges. Plasma levels
were at steady state during anesthesia (MED 2.194 ± 0.073; XYL 708 ± 18.791 ng
mL−1). During recovery lateral recumbency (MED 42.7 ± 2.51; XYL 34.3 ± 2.63min;
p = 0.027) and time to standing (MED 62.0 ± 2.86; XYL 48.8 ± 3.01min; p = 0.002)
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were significantly shorter in group XYL compared to group MED. Recovery scores did
not differ significantly between groups.
Conclusion and Clinical Relevance: In horses anesthetized with isoflurane and
medetomidine or xylazine, xylazine maintained higher MAP, reduced the dobutamine
consumption and recovery time, whilst overall recovery quality was unaffected.
Keywords: anesthesia, horse, isoflurane, medetomidine, alpha2-adrenergic agonists, equine, equisedative,
recovery
INTRODUCTION
Volatile anesthetic agents are commonly used in horses
undergoing surgery; however, they cause cardio-respiratory
depression (1) and they contribute to the equine anesthesia-
associated morbidity and mortality (2, 3). Therefore, a balanced
anesthetic protocol with partial intravenous anesthesia (PIVA)
using one or more complementary agents is a common concept
in modern equine general anesthesia (4–6). The aim of PIVA is
to improve analgesia and to reduce the amount of the volatile
anesthetic agents (7), in order to maintain good intraoperative
cardiopulmonary function followed by smooth and coordinated
recovery (4, 5, 8). Various alpha2-adrenergic agonists constant
rate infusions (CRI) have been used in anesthetized horses for
this purpose (9–13).
Half-lives of medetomidine (4.14min) (14) and xylazine
(5.9min) (15) are relatively short and onset of action of the drugs
is quick. Both drugs have been shown to result in constant plasma
levels when administered as CRIs preceded by a bolus (15, 16).
Medetomidine, a potent, short acting, highly selective
and specific alpha2-adrenergic agonist [selectivity ratio
(alpha2:alpha1) 1,620:1] (17), has been shown to reduce the
minimum alveolar concentration of isoflurane and provide
potent analgesia (5, 18).
The reported side-effects after injection of a single IV bolus
(dose) of medetomidine in non-anesthetized horses and ponies
are brady-arrhythmias, increase in systemic vascular resistance
and arterial blood pressure, and decrease of cardiac output
(14, 19, 20). However, these effects are transitory and are not
worsened by a following infusion (19). Even though it is not
registered for horses in Europe or the United States, there are
numerous reports about its use in equine clinical practice (6,
18, 21, 22). The administration of medetomidine CRI produced
better recoveries than lidocaine or S-ketamine CRIs in isoflurane
anesthetized horses (1, 23).
Xylazine, another alpha2-adrenergic agonist registered for
horses also provides sedation, analgesia and muscle relaxation
(24). It is the least selective alpha2-agonist [selectivity ratio
(alpha2:alpha1) 160:1] and widely used as a premedicant (16, 25),
but reports about its use as CRI in balanced anesthesia regimes
are sparse (11).
Cardiopulmonary effects following xylazine bolus
administration are also similar to other alpha2-adrenergic
agonists, but during CRI the effects are minimal in particular
if compared to romifidine CRI (26). In comparison to
medetomidine cardiovascular effects of xylazine have been
demonstrated in ponies to be less and shorter lasting (27).
However, it remains to be tested if the dose rates investigated
were equipotent. A bolus administration of IV xylazine at
0.5 and 1.0mg kg−1 reduced isoflurane MAC by 25 and
34%, respectively (28).
The aim of the present study was to compare the
intraoperative cardiovascular effects and recovery of xylazine
vs. medetomidine isoflurane PIVA in horses undergoing elective
surgery. The hypothesis of our study was that 7 µg kg−1
medetomidine followed by 3.5 µg kg−1 h−1 results in similar
effects as 1.1mg kg−1 xylazine followed by 0.69mg kg−1 h−1.
MATERIALS AND METHODS
Study Design and Animals
This prospective randomized blinded clinical study was
performed with the ethical approval of the local committee for
animal experimentation (ZH176/17). Written owner’s consent
was obtained.
Sixty client-owned horses of various breeds presented for
elective surgeries were included in the study. This number was
considered adequate to ascertain that the doses of medetomidine
and xylazine tested were suitable regarding their influence on
the concentration of isoflurane necessary to maintain anesthesia.
In order to detect if isoflurane is increased from 1.1 ± 0.135 to
1.2% with a power of 0.8 and an alpha error of 0.05, 29 horses
in each group are necessary. Inclusion criteria were body weight
(≥200 kg), age (2–20 years), physical status American Society of
Anesthesiologists 1 or 2. Exclusion criteria were surgery of the
head, need of assisted recovery and general anesthesia in the
previous 6 months. Food, but not water, was withheld 8–12 h
prior to anesthesia. Each patient was randomly assigned to either
group MED (medetomidine) or XYL (xylazine) at the beginning
of the experiment, using one of sixty previously prepared opaque
envelopes (containing group allocation), opened by a person who
was not involved in the study. Demographic data was recorded
on a separate data sheet (AW). All anesthetic procedures were
performed by the same experienced anesthetist (AW), who was
unaware of the treatment at any time until the end of the study.
Study Protocol
Prior to sedation, the skin over one jugular vein was clipped
and aseptically prepared. After infiltration with mepivacaine
2% (Mepivacain HCL 2%; Sintetica S.A., Switzerland), a 14
gauge catheter (Secalon-T with FlowSwitch; Argon Critical Care
Systems, Singapore) was placed.
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At 30–60min before induction of anesthesia, patients in
both groups received 30’000 I.E. kg−1 of penicilline Na+
(Penicillin Natrium Streuli ad us. vet.; Streuli Pharma AG,
Switzerland), 6.6mg kg−1 of gentamicine (Genta 10%.; CP-
Pharma, Switzerland) intravenously (IV). Horses undergoing soft
tissue surgeries received flunixin meglumine 1.1mg kg−1 IV
(Fluniximin ad us. vet.; Graeub AG, Switzerland) and horses
undergoing orthopedic surgeries received phenylbutazone 4mg
kg−1 IV (Butadion ad us. vet.; Streuli Pharma AG, Switzerland).
All horses received 0.03mg kg−1 of acepromazine (Prequillan
ad us vet.; Arovet AG, Switzerland) IM. Immediately before
induction of anesthesia, horses were sedated with medetomidine
7 µg kg−1 IV (Medetor R© ad us. vet.; Virbac AG, Switzerland)
or xylazine 1.1mg kg−1 IV (Xylazin 2%; Streuli Pharma AG,
Switzerland) depending on group allocation. Medication were
prepared by a veterinarian not involved in the study and diluted
with sodium chloride to a total volume of 40mL. One-third of the
dose was administered as a bolus in the stable, then the mouth
was rinsed and the horse walked to the induction area, where
the remaining two-thirds of sedative were injected IV slowly over
2min. Three minutes after the end of injection, depth of sedation
was assessed according to criteria published by Taylor et al. (29):
where sedation is indicated by head hight lower than withers
(eyes as benchmark), atonic lower lip, no reaction to snapping
fingers. If one or more than one condition indicating sedation
was not present, a supplemental dose of medetomidine 1 µg
kg−1 or xylazine 0.16mg kg−1 was administered IV, depending
on group allocation. Sedation was re-evaluated after 3min. This
procedure was repeated if necessary. The total amount of time
required for sedation was recorded.
Anesthesia was induced with IV diazepam 0.02mg kg−1 IV
(Valium R© 5mg; Roche Pharma AG, Switzerland) and ketamine
2.2mg kg−1 (Ketanarkon 100 ad us. vet.; Streuli Pharma AG,
Switzerland) mixed in one syringe. This was considered as
anesthesia time point zero (t0). Following induction of anesthesia
and tracheal intubation (silicone tubes, internal diameter 18–
30mm), the horses were hoisted onto a padded surgery table
and the endotracheal tube attached to a large animal circle
system (Tafonius; Hallowell Engineering &Manufacturing Corp.,
MA, USA). Isoflurane was delivered using a precision vaporizer
(Tec 7, Rothacher Medical GmbH, Heitenried, Switzerland). The
carrier gas for isoflurane (IsoFlo R©, Provet AG, Switzerland)
delivery consisted of a mixture of oxygen and air with an
initial inspiratory fraction of oxygen (FIO2) of 0.45–0.55. Every
5min, the depth of anesthesia was assessed and isoflurane supply
readjusted based on judgement by the main investigator, who
was unaware of the treatment. Isoflurane was delivered to the
end-tidal concentration (FE’Iso) required to keep the patient
immobile, to prevent nystagmus and hypertension, to provide
muscle relaxation and to allow evocation of sluggish palpebral
reflexes. Mechanical ventilation was commenced (tidal volume
10–12mL kg−1, I:E ratio 1:2.5–3, peak airway pressure below
25 cmH2O, variable respiratory rate) to an expired partial
pressure of CO2 between 45 ± 5 mmHg (5.3–6.6 kPa). Artificial
ventilation was started immediately after connection to the
breathing system and continued until the end of anesthesia. A
urinary catheter was placed in all horses immediately following
anesthesia induction and was left in place until the horse had
recovered from anesthesia. The amount of urine produced
was measured beginning as soon as the urinary catheter was
placed until the disconnection of the patient from the large
animal anesthesia machine. The urinary production during
recovery was not measured. Medetomidine 3.5 µg kg−1 h−1
or xylazine 0.69mg kg−1 h−1 for group MED and group
XYL, respectively, were started immediately after positioning
the animal on the surgery table, delivered IV by an infusion
pump (Phoenix D; Schoch Electronics, Switzerland). A 20
gauge catheter (SURFLO R©, Terumo Europe N.V., Belgium)
was placed percutaneously in a transverse facial artery for the
measurement of direct arterial blood pressures and to collect
blood for arterial blood gas analysis and plasma concentrations
of medetomidine and xylazine. A non-distensible extension line
filled with heparinized saline solution was connected to the
arterial catheter and to an electronic transducer (Monitoring
Kit Transpac IT; Abbott Ireland, Ireland) placed at level of
shoulder joint (dorsal recumbence) or manubrium sternum
(lateral recumbence), zeroed to atmospheric pressure and arterial
blood pressures were obtained. HR, respiratory rate (RR),
end expiratory carbondioxide tension (PE’CO2), expiratory
isoflurane concentration (ETIso) as well as arterial blood
pressures were monitored continuously with a multiparameter
monitor (Datex-Ohmeda-Cardiocap/5’) and manually recorded
every 5min. After anesthesia induction, dobutamine (Dobutrex;
Teva Pharma AG, Switzerland) was started at a rate of 40
µg kg−1 h−1 via an infusion pump (Volumed R© µVP5005;
Arcomed, Switzerland). In order to keep the MAP values stable,
the rate of dobutamine was readjusted every 5min based on a
prepared rate scale in dependence on the MAP (<65 mmHg:
70 µg kg−1 h−1; 65–70 mmHg: 60 µg kg−1 h−1; 71–75
mmHg: 50 µg kg−1 h−1; 76–80 mmHg: 40 µg kg−1 h−1; 81–
85 mmHg: 30 µg kg−1 h−1; 86–90 mmHg: 15 µg kg−1 h−1;
>90 mmHg: 0 µg kg−1 h−1). Intravenous crystalloids (Ringer-
Laktat; Bichsel AG, Switzerland) were administered IV at a rate
of 8–11mL kg−1 h−1. If despite 70 µg kg−1 h−1 dobutamine
the MAP remained below 65 mmHg or if the HR increased
to a value higher than 1.5 times HR at t30, a bolus of 5mL
kg−1 lactated Ringer solution was administered over 10min.
This bolus application was repeated once. If MAP did not rise
above 65 mmHg a 2mL kg−1 IV bolus of tetrastarch (Voluven
balanced 6%; Fresenius Kabi AG) was administered in addition
to the dobutamine infusion. The tetrastarch bolus application
was repeated until MAP > 65 mmHg. If nystagmus or incessant
fighting against the ventilator occurred, ketamine 0.1mg kg−1
IV was administered. In case of movement, thiopental 0.5mg
kg−1 IV (Thiopentalum natricum; Spedalia AG, Switzerland)
was given every minute until movement stopped. At time
points t30, t60, t90, t150, and t210, arterial blood samples were
drawn anerobically using pre-heparinized syringes (BD A-Line;
Becton, Dickinson and Co., UK), and analyzed immediately
(RAPIDPoint R©500; Siemens, Germany). Analysis included pH,
arterial partial pressure of oxygen (PaO2) and carbon dioxide
(PaCO2), base excess (BE) and electrolytes (Na
+, K+, Ca2+,
Cl−) as well as arterial lactate (Lac). If a PaO2 < 80 mmHg
(10.7 kPa) was detected, FIO2 was increased to 1.0. If a PaO2
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< 60 mmHg (8 kPa) was detected, salbutamol (Ventolin R©
GlaxoSmithKline AG, Müchenbuchsee, Switzerland) 2 µg kg−1
was administered intratracheally. Thirty minutes prior to the end
of anesthesia, morphine 0.1mg kg−1 (Morphine HCL 10mg;
Sintetica SA, Switzerland) was administered IM. At the end of
surgery, all infusions and mechanical ventilation were stopped
and horses were hoisted from the table to a padded recovery
box. From the moment of disconnection of the horse from the
anesthetic machine, the recovery timing was started. Ventilation
was assisted using a demand valve (JD Medical, Phoenix,
Arizona, USA) twice per minute until the horse started to breath
spontaneously. Subsequently, medetomidine 2 µg kg−1 (group
MED) or xylazine 0.3mg kg−1 (group XYL) was administered
IV slowly over 2min. If at that timepoint horses either already
moved or showed excessive nystagmus the post anesthesia dose
of either medetomidine or xylazine was doubled. Oxygen was
administered (15 L min−1) through the endotracheal tube (ETT).
The horse’s tracheas were extubated 15min after disconnection of
the horse from the anesthetic machine. Before removing the ETT,
5mL phenylephrine 0.15% drops (Phenylephrin hydrochloridum
1.5mg mL−1; Volksapotheke Schaffhausen, Switzerland) were
instilled into each nasal cavity. Horses were allowed to recover
without assistance. Times to attain sternal and standing positions
were noted. Themain anesthetist assessed recovery quality. Three
different scoring systems (6, 30, 31) were used for assessment.
Plasma medetomidine and xylazine concentrations were
determined from blood samples taken from the jugular vein
not used for drug injection or (during anesthesia) from the
arterial catheter. Blood was sampled before premedication, after
sedation, t30, t60, t90, t150, t210, just before the postoperative
sedation and 5–10min after reaching standing position. Before
each sampling, 10mL of blood was withdrawn, then 6mL of
blood was collected into lithium-heparin containing vacutainers
(6mL Vacutainer R©, Becton Dickinson, Meylan Cedex, France).
This blood was centrifuged without delay and the plasma
frozen at −80◦C until analyses. Plasma samples were analyzed
by liquid chromatography-tandem mass spectrometry (LC-
MS/MS). For xylazine determination, a 200 µL aliquot of
plasma was added with the internal standard (xylazine-d6)
and 800 µL of acetonitrile, then 100 µL of the supernatant
were transferred into a vial containing 900 µL of 0.1% formic
acid aqueous solution prior to injection. As for medetomidine,
internal standard medetomidine-d3 was added to 300 µL of
plasma and a liquid-liquid extraction with 900 µL of ethyl
acetate was performed. The dry residue of the supernatant
was reconstituted in a 0.1% formic acid in water: acetonitrile
90:10 (v/v) solution and injected. The LC system was a Waters
Acquity UPLC binary pump, equipped with a Waters BEH
C18 (2.1 × 50mm, 1.7 um) column (Waters, Milford, MA,
USA). The mobile phase was a mixture of acetonitrile and 0.1%
formic acid in water, at a flow rate of 0.3mL min−1 under
programmed conditions. The detector was a Waters Quattro
Premier XE triple quadrupole mass spectrometer (Waters,
Milford, MA, USA) with positive electrospray ionization source
(ESI+), operating in multiple reaction monitoring (MRM)
mode. The specific transitions observed for each analyte were:
221.0→ 89.8 and 163.7 for xylazine; 227.0→ 169.8 for xylazine-
d6; 201.0→ 94.7 and 67.7 for medetomidine; 204.0→ 97.6
for medetomidine-d3. The two methods were validated in
accordance with EMEA/CHMP/EWP/192217/2009 guidelines
before the experiment.
Statistical Analysis
Data distribution was tested with the Shapiro-Wilk test
of normality. Depending on distribution, t-test or Mann-
Whitney test was used to assess differences between groups
in terms of weight, age, anesthesia duration, recovery times,
intra-anesthetically administered lactated Ringer solution,
dobutamine, injected ketamine or thiopental and scores.
Repeatedly measured parameters were analyzed using a two-way
repeated-measures analysis of variance (ANOVA) followed by
Holm-Sidak multiple comparisons test to analyse differences
between groups and over time. Chi-square test was used to
evaluate significant group differences between required doses of
sedation. HR and MAP analyses was restricted to time point t20-
t120 and t30-t120, respectively. Significance was considered when
p ≤ 0.05. Statistical analysis was performed using SigmaStat
3.5 (Systat Software, CA, USA). Results of parametric data are
expressed as mean ± standard error of the mean and results of
non-parametric data as median (range).
RESULTS
Sixty horses were randomly allocated into two groups (MED or
XYL). Due to a mistake in the arrangement 29 horses were in
group XYL and 31 horses in group MED.
One horse in group XYL showed seizures of unknown
origin during anesthesia and was completely excluded from
data analyses. One horse in group MED needed treatment
with salbutamol 2 µg kg−1 intratracheally but was excluded
completely from data analysis due to technical problems 10min
later. Furthermore, one horse from each group had to be
excluded from the recovery scoring due to intraoperative
decisions for assisted recovery (XYL) or bleeding during
recovery (MED). Otherwise, numbers of horses from which data
originated are indicated in the corresponding table or figure
(Tables 1–3 and Figure 1).
No significant differences in age (MED: 11.5 ± 0.8; XYL: 11.1
± 1.0 years; p = 0.760); body weight (MED: 532 ± 14; XYL: 520
± 19 kg; p = 0.599), breed (46 warmbloods; 5 thoroughbreds;
8 ponies), BCS (4 horses BCS 2/5; 47 horses BCS 3/5; 7 horses
BCS 4/5; 1 horse BCS 5/5), sex (13 mares; 17 stallions; 29
geldings), type of recumbency (30 dorsal recumbency; 29 lateral
recumbency), type of procedure (28 orthopedic procedures; 31
soft tissue procedure) or total duration of anesthesia (MED:
145.4 ± 6.3; XYL: 148 ± 6.8min; p = 0.777) were identified
between groups. During preoperative sedation six horses in
group XYL showed tumbling before the full dose of xylazine was
administered. Further administration of xylazine was stopped
immediately and sedation criteria evaluated after 3min. All six
horses pervaded the criteria and anesthesia was induced. In both
groups some horses (MED n = 4; XYL n = 2) did not fulfill the
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TABLE 1 | Mean ± SEM of venous blood-gas values, pH, lactate concentrations, total hemoglobin, base excess in horses with medetomidine isoflurane (group MED) or
xylazine isoflurane (group XYL) balanced anesthesia.
Parameter Group Time point
B I R S
n MED 31 31 29 29
n XYL 28 27 28 25
PvCO2, mmHg (kPa) MED 46.89 ± 0.73 (6.3 ± 0.1) 48.20 ± 0.73 (6.4 ± 0.1) 62.27 ± 0.76 (8.3 ± 0.1)
# 52.11 ± 0.76 (6.9 ± 0.1)#
XYL 46.58 ± 0.77 (6.2 ± 0.1) 49.14 ± 0.78 (6.6 ± 0.1)# 63.02 ± 0.77 (8.4 ± 0.1)# 53.54 ± 0.82 (7.1 ± 0.1)#
PvO2, mmHg (kPa) MED 34.35 ± 0.80 (4.6 ± 0.1) 28.44 ± 0.81 (3.8 ± 0.1)
# 47.62 ± 0.83 (6.3 ± 0.1)*# 33.64 ± 0.83 (4.5 ± 0.1)
XYL 34.90 ± 0.83 (4.7 ± 0.1) 28.33 ± 0.85 (3.8 ± 0.1)# 44.90 ± 0.83 (6.0 ± 0.1)*# 33.85 ± 0.90 (4.5 ± 0.1)
pH MED 7.41 ± 0.004 7.39 ± 0.004# 7.32 ± 0.004# 7.40 ± 0.004#
XYL 7.41 ± 0.004 7.38 ± 0.004# 7.32 ± 0.004# 7.39 ± 0.004#
Lactate (mmol L−1) MED 0.63 ± 0.16 0.69 ± 0.16 2.02 ± 0.17# 2.03 ± 0.17#
XYL 0.62 ± 0.17 0.70 ± 0.17 1.58 ± 0.17# 1.80 ± 0.19#
Hb (g dL−1) MED 12.61 ± 0.21 12.11 ± 0.20 10.99 ± 0.22# 11.60 ± 0.22#
XYL 12.61 ± 0.22 11.69 ± 0.22# 10.68 ± 0.22# 12.06 ± 0.23
BE (mmol L−1) MED 4.00 ± 0.29 2.64 ± 0.29# 4.01 ± 0.30 5.72 ± 0.30#
XYL 3.41 ± 0.30 2.02 ± 0.31# 4.43 ± 0.30# 5.90 ± 0.32#
Significant differences (p < 0.05) between groups are indicated by * and significant changes compared to B in the same group are indicated by #.
PvO2, PvCO2, venous oxygen and carbon dioxide partial pressures; Lac, lactate concentration; Hb, total hemoglobin; BE, base excess; B, Baseline; I, Induction; R, Recovery; S, Standing.
TABLE 2 | Mean ± SEM of arterial blood-gas values, pH, lactate concentrations, total hemoglobin, base excess in horses with medetomidine isoflurane (group MED) or
xylazine isoflurane (group XYL) balanced anesthesia.
Parameter Group Time point
t30 t60 t90 t150
n MED 31 30 26 8
n XYL 27 27 26 10
PaCO2, mmHg (kPa) MED 50.57 ± 0.49 (6.7 ± 0.07) 52.89 ± 0.51 (7.1 ± 0.07)*
# 54.82 ± 0.56 (7.3 ± 0.07)*# 55.56 ± 1.10 (7.4 ± 0.15)#
XYL 51.19 ± 0.52 (6.8 ± 0.07) 51.03 ± 0.54 (6.8 ± 0.07)* 52.11 ± 0.55 (6.9 ± 0.07)* 52.45 ± 0.96 (7.0 ± 0.13)
PaO2, mmHg (kPa) MED 153.97 ± 5.16 (20.5 ± 0.69) 151.34 ± 5.45 (20.2 ± 0.73) 146.47 ± 5.90 (19.5 ± 0.79) 152.00 ± 11.40 (20.3 ± 1.52)
XYL 151.03 ± 5.53 (20.1 ± 0.74) 148.56 ± 5.53 (19.8 ± 0.79) 155.82 ± 5.68 (20.8 ± 0.76) 145.30 ± 10.00 (19.4 ± 1.33)
pH MED 7.35 ± 0.003 7.35 ± 0.003 7.35 ± 0.003 7.36 ± 0.006
XYL 7.35 ± 0.003 7.36 ± 0.003 7.36 ± 0.003 7.38 ±0.006#
Lactate (mmol L−1) MED 1.61 ± 0.03 1.83 ± 0.03# 1.9 ± 0.03*# 2.00 ± 0.06#
XYL 1.47 ± 0.03 1.60 ± 0.03# 1.65 ± 0.03*# 1.56 ± 0.06#
Hb (g dL−1) MED 11.32 ± 0.12 10.6 ± 0.12# 10.40 ± 0.13# 10.88 ± 0.25
XYL 11.62 ± 0.12 10.76 ± 0.13# 10.35 ± 0.13# 9.52 ± 0.24#
BE (mmol L−1) MED 2.37 ± 0.20 2.00 ± 0.21# 2.87 ± 0.23# 4.55 ± 0.44#
XYL 1.56 ± 0.21 2.10 ± 0.22 2.50 ± 0.22# 4.05 ± 0.39#
Significant differences (p < 0.05) between groups are indicated by * and significant changes compared to t30 in the same group are indicated by #.
PaO2, PaCO2, arterial oxygen and carbon dioxide partial pressures; Lac, lactate concentration; Hb, total hemoglobin; BE, base excess; t30−150, timepoints in minutes after induction.
sedation criteria and required one or more supplemental dose.
The median dose of sedation necessary to fulfill sedation criteria
prior to anesthesia induction was 7 (7–10) µg kg−1 in group
MED and 1.1 (0.8–1.3) mg kg−1 in group XYL. There was no
significant difference in the time from the start of sedation to
induction of anesthesia between groups [MED: 6 (3–8); XYL: 7
(4–14) min; p= 0.101].
No significant difference was found between groups regarding
mean ET’Iso concentrations (MED: 1.1 ± 0.02; XYL: 1.1 ±
0.02%; p = 0.267). Nevertheless, group-independent changes
over time were significant with ET’ISO increasing over time
compared to t20.
Figure 1 displays MAP and HR. MAP was within the
targeted values but significantly higher with xylazine compared
to medetomidine at time points t70 (p = 0.007), t80 (p = 0.005),
t90 (p = 0.017), t110 (p = 0.013) and t120 (p = 0.015). No
differences between groups were detected for HR (p = 0.85).
However, an increase in HR over time was observed for both
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TABLE 3 | Mean ± SEM of electrolytes in horses with medetomidine isoflurane (group MED) or xylazine isoflurane (group XYL) balanced anesthesia.
Parameter Group Time point
B (venous) I (venous) t30 (arterial) t60 (arterial) t90 (arterial) t150 (arterial) R (venous) S (venous)
n MED 31 31 31 30 26 8 29 29
n XYL 28 27 27 27 26 10 28 25
Na+ (mmol L−1) MED 135.99 ± 0.31 135.94 ± 0.30 135.09 ± 0.31 135.83 ± 0.31
XYL 135.81 ± 0.32 136.89 ± 0.32 134.99 ± 0.31# 136.77 ± 0.34
K+ (mmol L−1) MED 3.58 ± 0.04 3.49 ± 0.04 3.71 ± 0.04# 3.91 ± 0.04#
XYL 3.67 ± 0.04 3.55 ± 0.04 3.68 ± 0.04 3.98 ± 0.04#
Ca2+ (mmol L−1) MED* 1.46 ± 0.007 1.45 ± 0.007 1.30 ± 0.007*# 1.28 ± 0.007*#
XYL* 1.49 ± 0.007 1.48 ± 0.007 1.34 ± 0.007*# 1.31 ± 0.007*#
Cl−1 (mmol L−1) MED 100.45 ± 0.24 100.58 ± 0.24 99.31 ± 0.25# 98.24 ± 0.25#
XYL 100.39 ± 0.25 100.44 ± 0.26 99.18 ± 0.25# 98.28 ± 0.27#
Na+ (mmol L−1) MED 134 ± 0.25 134.04 ± 0.26 134.51 ± 0.30# 134.54 ± 0.56#
XYL 133.26 ± 0.27 133.64 ± 0.28 134.32 ± 0.29 134.15 ± 0.50
K+ (mmol L−1) MED 3.6 ± 0.02 3.5 ± 0.02 3.50 ± 0.03 3.69 ± 0.05
XYL 3.54 ± 0.02 3.53 ± 0.03 3.53 ± 0.03 3.52 ± 0.05
Ca2+ (mmol L−1) MED 1.38 ± 0.005 1.34 ± 0.005# 1.32 ± 0.006# 1.29 ± 0.011#
XYL 1.4 ± 0.005 1.36 ± 0.006# 1.34 ± 0.006# 1.32 ± 0.010#
Cl−1 (mmol L−1) MED 99.77 ± 0.20 100.10 ± 0.20 100.12 ± 0.22 100.13 ± 0.43
XYL 99.61 ± 0.20 100.22 ± 0.21# 100.19 ± 0.22 101.00 ± 0.38#
Significant differences (p < 0.05) between groups are indicated by * and significant changes compared to B or t30 in the same group are indicated by #.
Na+, ionized sodium; K+, ionized potassium; Ca2+, ionized calcium; Cl−, ionized chlorine; B, Baseline; I, Induction; R, Recovery; S, Standing; t30−150, timepoints inminutes after induction.
FIGURE 1 | Heart rates (HR) and mean arterial blood pressures (MAP) in horses during medetomidine isoflurane (group MED) or xylazine isoflurane (group XYL)
balanced anesthesia (mean ± SEM). Significant differences between groups is marked with a double circle ( ). Time points with significant difference to t20 are
marked with asterisk (*). Represented on the x-axis are minutes after anesthesia induction.
groups (p < 0.001). Dobutamine requirement was significantly
higher with medetomidine (MED: 36 ± 1.8; XYL: 24 ± 1.8 µg
kg−1 h−1; p = 0.0003). Five horses in group MED required
between one and three lactated Ringer solution boluses and
one of them needed two boluses of tetrastarch, while in
group XYL only three horses received one bolus of lactated
Ringer solution to achieve the targeted values of MAP and
HR. Results of venous and arterial pH and arterial blood
gases are found in Tables 1, 2 and those of electrolytes,
lactate and hemoglobin in Table 3. There were some changes
over time and very minimal differences in arterial partial
pressure of CO2 (PaCO2), venous partial pressure of O2 (PvO2),
lactate, hemoglobin concentrations and Ca2+ between the
groups (Tables 1–3).
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FIGURE 2 | Recovery time in horses after medetomidine isoflurane (group
MED) or xylazine isoflurane (group XYL) balanced anesthesia (mean ± SEM).
Significant differences between groups is marked with a double circle ( ).
Multiple horses in both groups (MED n = 18; XYL n = 15)
required one or several boluses of ketamine. Two horses in MED
and three horses in XYL were administered a single dose of 0.5 or
1.0mg kg−1 thiopental, either to allow intubation (MED n = 2;
XYL n = 2) or because of limb movement during surgery (XYL
n = 1). There was no significant difference in urine production
between the two groups [MED: 6.4 (1.6–14.6); XYL: 5.0 (1.6–
15.4) mL kg−1 h−1; p= 0.522].
All horses started to breathe spontaneously within 3–4min
after disconnection from the breathing system and post sedation
was administered right thereafter. Total recovery time was
significantly longer with medetomidine [MED: 64 (30–115);
XYL: 47.5 (24–92) min; p = 0.002] (Figure 2). The pivotal
phase during recovery was lateral recumbency time, which was
significantly longer with medetomidine [MED: 41 (19–69); XYL
31.5 (12–60) min; p = 0.027]. No significant difference between
groups in the other recorded time spans were detected (in
minutes): time to extubation [MED: 15 (11–40); XYL: 15 (8–30);
p= 0.114]; time from sternal to standing [MED: 15 (0–51); XYL:
11 (0–36); p = 0.615]. Recovery was generally of good quality
and showed no significant differences between groups in all three
scoring systems. In score Sacks et al. (6) where one is best and five
is worst recovery quality, 16 horses of group MED and 14 horses
of group XYL were classified score 1. The worst recovery scores
recorded were from three horses in group MED with a score of
3 and one horse in group XYL with a score of 4 [MED: 1.6 (1–
3); XYL: 1.7 (1–4); p = 0.837]. In the scoring system by Valverde
et al. (31) where recovery quality can range between 8 and 26 plus
number of attempts to stand scores were MED: 14 (9–25); XYL:
12 (9–27); p= 0.627. Scores of the third scoring system (30) used
can range from 8 to 70 plus number of attempts to sternal plus
number of attempts to stand [MED: 23 (12–56); XYL: 24 (10–52);
p= 0.712]. Two horses, one of each group, were administered an
additional bolus of either medetomidine or xylazine for recovery,
as they showed rapid nystagmus upon arrival in the recovery box
which did not cease following the administration of the normal
sedative dose.
Plasma concentrations of both drugs showed a constant level
during general anesthesia (Figure 3).
DISCUSSION
The current study investigated in horses anesthetized with
isoflurane whether the use of medetomidine compared to
xylazine for balanced anesthesia resulted in clinically relevant
differences in cardiopulmonary function or recovery from
anesthesia. The only detectable clinically relevant difference was
a shorter recovery following the use of xylazine. Further at
some timepoints slightly lower mean arterial blood pressures in
combination with a lower need for dobutamine with xylazine
were observed. As arterial blood pressures were easily maintained
within clinically normal values, the relevance of this finding yet
has to be determined.
There is no doubt that even with modern anesthesia
techniques and optimized monitoring systems fatality rate in
horses is too high and studies to establish safer anesthesia
techniques are warranted. Since most anesthetists have stopped
to use halothane and use isoflurane or sevoflurane instead
(32), less horses have been reported to die intraoperatively,
but fatal problems during recovery are predominant (2, 33).
Thus, anesthesia techniques resulting in calm recovery should be
established without delay.
Alpha2-adrenoceptor agonists based PIVA techniques have
been used since about two decades (34, 35) and in particular
medetomidine and more recently dexmedetomidine have been
tested in many horse studies (6, 10, 12). As those drugs are
short acting (19, 36, 37) they can be easily titrated to effect
and recovery, even after prolonged anesthesia, is usually prompt
and of better quality than following lidocaine or ketamine
based PIVA protocols (12, 38). As in European countries
neither medetomidine nor dexmedetomidine are licensed for
food producing animals PIVA protocols including licensed
alpha2-adrenoceptor agonists are warranted. In conscious horses
xylazine, in comparison to the other two for horses licensed
alpha2-adrenoceptor agonists detomidine and romifidine, has
a similar short duration of action as medetomidine and
dexmedetomidine (20, 39, 40). Also, distribution half-lives of
xylazine are comparable to medetomidine and dexmedetomidine
(15, 41). Romifidine and detomidine are longer acting and show
more cardiovascular effects than xylazine (20, 42).
We chose to compare medetomidine with xylazine as
dexmedetomidine for sedation of clinical patients proven to be
not as reliable as medetomidine (6, 43) and dose rates necessary
to achieve good sedation before anesthesia induction were
considered too variable to be a safe alternative for daily practice.
The present study detected some differences in
cardiopulmonary function between the two regimes tested.
If the higher arterial blood pressures with xylazine are a result of
more vasoconstriction or a better cardiac output will have to be
tested in a study with detailed monitoring of cardiopulmonary
function. In conscious horses with xylazine at the same dose as
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FIGURE 3 | Medetomidine or xylazine plasma concentrations in horses before, during and following medetomidine isoflurane (group MED) or xylazine isoflurane
(group XYL) balanced anesthesia (mean ± SEM).
used in the present study, effects on cardiopulmonary function
were remarkably low (42). It is however noteworthy that with a
very low dose dobutamine MAP stayed within targeted values in
both groups, but in the XYL group about 30% less dobutamine
was needed. We did not use LIDCO to measure cardiac output
even though it would be the only safe method to measure cardiac
output in clinical cases, as several of the drugs used in the present
study have experimentally been shown to have an influence on
the measurements of LIDCO (44).
In conscious horses and ponies xylazine and medetomidine
at the dose rates used in the current study, cause significant
cardiopulmonary depression following bolus administration (19,
20, 42). However, at steady state plasma levels cardiopulmonary
function returns to nearly pre-sedation values (19, 42). The
plasma levels of both drugs were stable during drug infusion
and remarkably similar to the plasma levels measured in horses
sedated with similar dose rates of xylazine (26) and slightly higher
than what has been reported in standing ponies (19). Although in
both groups at the end of CRI following transport into recovery
a relevant bolus dose was given to keep the horses sedated and
prevent them from an untimely recovery, plasma levels showed a
rapid decline, probably as a result of a fast decrease of isoflurane
coupled to better liver and general perfusion influencing volume
of drug distribution and metabolism.
Acid base balance, electrolytes, lactate and glucose
concentrations as well as arterial blood gases remained within
clinically acceptable ranges and differences don’t seem to be
clinically relevant. The amount of urine produced in both groups
was considerable and needs to be taken into consideration, when
fluid therapy is planned. The use of an intraurethral catheter is
advisable in any case.
Bryant et al. (39) showed that medetomidine produces more
ataxia than xylazine, so a more ataxic recovery might be
expected following medetomidine CRI. Bryant et al. (39) tested
medetomidine at a considerably higher dose rate (MED 10 µg
kg−1 IV) than what was used here for recovery. Therefore,
recovery quality in the present study was not different between
the groups, as sedative doses used were adequate and not causing
additional ataxia. We used 3 different previously described
scoring systems (6, 30, 31) to judge recovery as each system
evaluates recovery in a slightly different way. We wanted to
ascertain that our results are not a consequence of the scoring
system used but rather of the medication tested. The groups were
similar concerning factors that might affect recovery quality such
as anesthesia duration, weight and recumbency during surgery
(45, 46). As the incidence of poor recoveries in this study was
low and no ASA III-IV horses were included we cannot conclude
with only 56 observed recoveries, if the use of either drug is
really equal concerning recovery quality. A power analyses of our
data revealed that a total of 498 comparable horse anesthetics
would have to be investigated to detect with a power of 80%
and an alpha error of 0.05, if the incidence of two bad quality
recoveries [score 4 and 5 in comparison to 1, 2, or 3 according
to Sacks et al. (6)] can be reduced to one, with one or the other
PIVA regime.
With xylazine in our study horses remained for a shorter time
period in lateral recumbency and recovered overall faster. We
can only speculate if this is a result of a quicker redistribution
or metabolism of xylazine or a stronger sedative/analgesic effect
of themore specific alpha2-adrenoceptor agonistsmedetomidine.
Theoretically, recoveries are of better quality if horses don’t
get up too quickly, as it allows for the inhalant anesthetic to
be blown off before the horse attempts to stand up. But with
the shorter acting dexmedetomidine recovery from balanced
anesthesia was of better quality than following medetomidine
PIVA (6), despite otherwise more or less identical effects of
the two drugs (at equipotent doses). On the other hand, will
prolonged recumbency cause atelectasis and poor perfusion
of dependent muscle groups resulting in myopathy and
neuropathy. Therefore, the use of xylazine, in particular for
prolonged anesthesia’s, in compromised patients might prove to
be advantageous.
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The major limitation of this study is that no sample
size calculation with a main outcome was performed.
A further weakness is that the depth of anesthesia
was judged by a subjective method, but the anesthetist
was the same for all procedures and was blinded to
treatment. Also, for different procedures horses received
two different non-steroidal anti-inflammatories, flunixine
and phenylbutazone, but this was equally distributed to
the groups.
CONCLUSION
In conclusion PIVA with isoflurane and a CRI of xylazine
(0.69mg kg−1 h−1) compared to medetomidine (3.5 µg
kg−1 h−1) resulted in slightly better MAP, lower need for
dobutamine and a faster recovery, whilst overall recovery quality
was unaffected.
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